Cardio Round-up: Metformin Prevents Mortality; HFSA 2019 Highlights; and More

This week’s edition looks some potential cardiovascular benefits from metformin, a worrying trend in heart failure, an interventional update, and other news from the Heart Failure Society of America Scientific Sessions (HFSA 2019).

Metformin Lowers All-cause Mortality in Type 2 Diabetics

The commonly prescribed therapy metformin was associated with a reduction in all-cause mortality in patients with type 2 diabetes, but not with cardiovascular mortality. This analysis of the SAVOR-TIMI 53 patient population sheds some light on the potential cardiac benefits of metformin in diabetic patients.

https://www.docwirenews.com/docwire-pick/cardiology-picks/metformin-mortality-type-2-diabetes/

Analysis: Heart Failure Burden Increasing Among Black Adults in U.S.

Reported from HFSA 2019, this important analysis shows that when it comes to overall heart failure burden among different groups in the U.S. population, disparities in overall heart failure burden persist between black adults and white adults.

https://www.docwirenews.com/docwire-pick/cardiology-picks/heart-failure-burden-black-adults-us/

LVAD Outflow Cannula Positioning Matters

More research our of HFSA 2019, this time for interventional cardiologists. If you’re implanting left ventricular assist devices, the positioning of the outflow cannula is critical for keeping down the risk for a subsequent stroke.

https://www.docwirenews.com/docwire-pick/cardiology-picks/outflow-cannula-stroke-lvad/

Other Heart Failure Society of America 2019 Highlights

In addition to the stories listed above, there were other interesting studies presented at the HFSA 2019 meeting in Philadelphia this past weekend. Of note, there were some interesting results in two different studies looking at spironolactone. Check out our coverage below!

https://www.docwirenews.com/docwire-pick/cardiology-picks/heart-failure-virtual-visits-spironolactone/